Scholar Rock's Apitegromab excels in Phase 2 trials, aiding muscle preservation with Tirzepatide. Click here to read why I think SRRK stock could be a Buy.

Scholar Rock has already applied for Food and Drug Administration approval of the drug, dubbed apitegromab, for patients with spinal muscular atrophy based on a Phase 3 trial that showed it could ...

David Hallal, Scholar Rock CEO, joins 'Fast Money' to talk its recent drug study results that found its drug taken in combination with Zepbound helped prevent muscle loss.

Scholar Rock shares had lost more than half of their value this year amid skepticism apitegromab could help people already on other drugs, Jefferies analyst Michael Yee wrote on Monday. The study’s ...

Scholar Rock executive sells over $16k in company stock ...

If Scholar Rock's obesity program, particularly SRK-439, demonstrates efficacy in preserving muscle mass while promoting weight loss, it could capture a significant share of this expanding market.

Scholar Rock’s stock has soared off the back of positive Phase III results from its spinal muscular atrophy (SMA) candidate. The Phase III SAPPHIRE trial (NCT05156320) evaluating Scholar Rock’s lead ...

Scholar Rock Holding Corp, based in Cambridge, Massachusetts, is a biotechnology firm focused on developing innovative treatments for serious diseases.

Shares of Scholar Rock Holding (NASDAQ: SRRK) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 and Nasdaq Composite were up modestly.

Scholar Rock Holding (NASDAQ:SRRK) Corporation (NASDAQ:SRRK) is a clinical-stage biopharmaceutical company at the forefront of developing innovative medicines for serious diseases, with a particular ...

CAMBRIDGE, Mass., September 04, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...